Membrane biophysics of enterotoxin mediated immunomodulation
肠毒素介导的免疫调节的膜生物物理学
基本信息
- 批准号:8386016
- 负责人:
- 金额:$ 22.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-02 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAntigensB-LymphocytesBindingBiophysicsCalciumCalcium SignalingCell membraneCellsChemosensitizationCholesterolCytoskeletonDataDevelopmentDiffuseDoseEmerging Communicable DiseasesEnterotoxinsEtiologyEventFluorescenceFluorescence Resonance Energy TransferFutureGangliosidesGoalsHealthHeatingHumanImageImmuneImmune responseImmunizationImmunologic AdjuvantsImmunologic ReceptorsInvestigationKnowledgeLipidsMass ImmunizationMeasurementMeasuresMediatingMembraneMembrane MicrodomainsMembrane ProteinsMethodsMicroscopyMissionModelingMolecularMonitorNoisePhosphorylationProcessProcess MeasurePropertyProtein KinaseProteinsPublic HealthReagentReceptor CellRegulationResearchRoleSignal TransductionSignaling ProteinSpectrum AnalysisStructureTechniquesTestingTimeToxinTweensVaccinesWorkbasecomputerized data processingdesignenterotoxin LTfluorescence imagingimaging modalityimmune functionimmunoregulationimprovedinnovationinterestmutantnovelpredictive modelingreceptorresearch studyresidenceresponse
项目摘要
DESCRIPTION (provided by applicant): There is a fundamental gap in our understanding of how Enterotoxin LT-II binding to angliosides in the cell membrane modulates the structure and function (e.g. membrane-associated signaling) of the immune-cell membrane. It is necessary to address this gap in order to understand and further the use of these molecules as adjuvants to potentiate the cellular immune response. Such adjuvant reagents are essential components of vaccines. Our long-term goal is to understand the impact of changes in cell membrane ultra-structure on immune-cell membrane signaling at the molecular level. The objective of this proposal is to determine how the adjuvant Enterotoxin LT-II alters the membrane ultra-structure to influence membrane signaling. In particular, we aim to determine the effects of Enterotoxin binding on interactions between membrane proteins and cholesterol-dependent and -independent membrane domains, or nanoclusters. Based on preliminary data, our hypothesis is that adjuvant binding to gangliosides increases the stability of cholesterol-dependent nanoclusters, or the association of the receptor proteins with these clusters. The rationale for the proposed research is that a biophysical model of the influence of changes in membrane ultra-structure on cellular signaling will explain adjuvant potentiation of immune signaling. This hypothesis will be tested by quantifying the effects of Enterotoxin on the size, stability, and association of immune signaling proteins with lipid- and protein-membrane domains, and the membrane cytoskeleton; and by indentifying which membrane bound immune signaling processes are influenced by Enterotoxin binding. Our approach is extremely innovative and novel: We will establish advanced imaging methods which allow us to quantify membrane protein interaction with cholesterol-dependent and -independent nanoclusters and cytoskeleton continuously in intact cells. Our methods will enable a first real-time quantification of membrane structure modulation induced by enterotoxin binding. In addition, our study is uniquely suited to identify the relationship of changes in membrane structure to modulation of membrane function, e.g. cell signaling. By establishing this direct association between structural and functional changes in response to external perturbation will achieve an understanding of the role of the structure for function. The proposed research is significant because it will enhance our basic molecular understanding of the effect of enterotoxin like adjuvants, thus facilitating further investigation into optimizing the desired immune potentiating function. In addition, our results will expand the current understanding of the regulation of membrane structures such as lipid domains and the membrane cytoskeleton, and will elucidate their roles in natural immune function.
PUBLIC HEALTH RELEVANCE: Experiments to reveal the molecular processes by which enterotoxin-like agents modulate membrane ultra-structure and the mechanisms by which these changes influence immune signaling will guide the design of future immune adjuvants, which will have direct relevance to issues of public health. The broader impact of this project will be an improved understanding of how agents that modulate membrane structure influence cell signaling. Thus, the proposed research is relevant to NIH's mission that pertains to developing fundamental knowledge to help to protect and improve human health.
描述(由申请人提供):对于肠毒素LT-II如何与细胞膜中的血管紧张素转换酶结合调节免疫细胞膜的结构和功能(例如,膜相关信号),我们的理解存在一个根本的空白。有必要解决这一差距,以了解和进一步使用这些分子作为佐剂来增强细胞免疫反应。这种佐剂试剂是疫苗的基本成分。我们的长期目标是在分子水平上了解细胞膜超微结构的变化对免疫细胞膜信号的影响。这项建议的目的是确定佐剂肠毒素LT-II如何改变膜超微结构以影响膜信号转导。特别是,我们的目标是确定肠毒素结合对膜蛋白与胆固醇依赖和独立的膜域或纳米簇之间相互作用的影响。基于初步数据,我们的假设是,佐剂与神经节苷脂结合增加了胆固醇依赖纳米簇的稳定性,或受体蛋白与这些簇的关联。提出这项研究的理由是,膜超微结构变化对细胞信号影响的生物物理模型将解释免疫信号的佐剂增强作用。这一假说将通过量化肠毒素对免疫信号蛋白的大小、稳定性、与脂质和蛋白质膜结构域以及膜细胞骨架的联系的影响来检验,并通过确定哪些膜结合的免疫信号过程受到肠毒素结合的影响来检验。我们的方法非常创新和新颖:我们将建立先进的成像方法,使我们能够量化完整细胞中依赖和独立于胆固醇的纳米簇和细胞骨架与膜蛋白的相互作用。我们的方法将首次实现对肠毒素结合诱导的膜结构调节的实时定量。此外,我们的研究特别适合于确定膜结构变化与膜功能调节的关系,例如细胞信号转导。通过建立结构和功能变化之间的这种直接联系来响应外部干扰,将实现对结构对于功能的作用的理解。这项研究具有重要意义,因为它将增进我们对肠毒素类佐剂作用的基本分子理解,从而促进进一步研究优化所需的免疫增强功能。此外,我们的结果将扩大目前对膜结构调节的理解,如脂结构域和膜细胞骨架,并将阐明它们在自然免疫功能中的作用。
与公共健康的相关性:揭示肠毒素样剂调节膜超微结构的分子过程以及这些变化影响免疫信号的机制的实验将指导未来免疫佐剂的设计,这将与公共健康问题直接相关。这个项目的更广泛的影响将是更好地理解调节膜结构的试剂如何影响细胞信号。因此,拟议的研究与NIH的使命有关,即发展基础知识,以帮助保护和改善人类健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arnd Pralle其他文献
Arnd Pralle的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arnd Pralle', 18)}}的其他基金
Membrane biophysics of enterotoxin mediated immunomodulation
肠毒素介导的免疫调节的膜生物物理学
- 批准号:
8502622 - 财政年份:2012
- 资助金额:
$ 22.89万 - 项目类别:
Deep Tissue Magneto-Genetic Cell-Stimulation for Neuroscience and Therapy
用于神经科学和治疗的深层组织磁遗传细胞刺激
- 批准号:
8328888 - 财政年份:2011
- 资助金额:
$ 22.89万 - 项目类别:
Deep Tissue Magneto-Genetic Cell-Stimulation for Neuroscience and Therapy
用于神经科学和治疗的深层组织磁遗传细胞刺激
- 批准号:
8478209 - 财政年份:2011
- 资助金额:
$ 22.89万 - 项目类别:
Deep Tissue Magneto-Genetic Cell-Stimulation for Neuroscience and Therapy
用于神经科学和治疗的深层组织磁遗传细胞刺激
- 批准号:
8179640 - 财政年份:2011
- 资助金额:
$ 22.89万 - 项目类别:
相似海外基金
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
在临床前小鼠和非人灵长类动物模型中确定 A 组链球菌疫苗抗原最有效的佐剂
- 批准号:
10577066 - 财政年份:2023
- 资助金额:
$ 22.89万 - 项目类别:
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10522591 - 财政年份:2022
- 资助金额:
$ 22.89万 - 项目类别:
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10884052 - 财政年份:2022
- 资助金额:
$ 22.89万 - 项目类别:
Establishment of postoperative adjuvant immunotherapy using peptide pool of tumor antigens in advanced esophageal cancer
晚期食管癌肿瘤抗原肽库术后辅助免疫治疗的建立
- 批准号:
15K10100 - 财政年份:2015
- 资助金额:
$ 22.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of cancer vaccine using adjuvant function encrypted artificial antigens
使用佐剂功能加密人工抗原开发癌症疫苗
- 批准号:
26430172 - 财政年份:2014
- 资助金额:
$ 22.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
- 批准号:
7849955 - 财政年份:2009
- 资助金额:
$ 22.89万 - 项目类别:
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
- 批准号:
7627172 - 财政年份:2009
- 资助金额:
$ 22.89万 - 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
- 批准号:
2068228 - 财政年份:1992
- 资助金额:
$ 22.89万 - 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
- 批准号:
3548034 - 财政年份:1992
- 资助金额:
$ 22.89万 - 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
- 批准号:
3548033 - 财政年份:1992
- 资助金额:
$ 22.89万 - 项目类别: